The Pioneer Fund Podcast

Jon Wang (Assort Health) on Building Voice AI for Healthcare at Scale

27 min · 21 de may de 2026
Portada del episodio Jon Wang (Assort Health) on Building Voice AI for Healthcare at Scale

Descripción

Millions of patients still wait on hold just to reach their doctor's office. Jon Wang, Founder & Co-CEO of Assort Health, decided that was unacceptable — and built the AI to fix it. In conversation with Dave Messina (GP, Pioneer Future of Health), Jon shares how Assort reached 130M+ patient interactions, why specialty-specific AI matters, and where voice AI in healthcare goes from here. Inflection is a new Pioneer Future of Health [https://health.pioneerfund.vc/?utm_source=luma] series where we bring together people at the edge of Health and AI — founders, operators, and bio-enthusiasts who are building the next decade of healthcare. Raw conversations, real insights, no hype.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de The Pioneer Fund Podcast!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

2 episodios

episode Pioneer Future Of Health & YC W26: The AI Health Tech Moment artwork

Pioneer Future Of Health & YC W26: The AI Health Tech Moment

In this episode, Jason Gray (Founder and General Partner, Pioneer Fund) and Dave Messina (General Partner, Pioneer Future of Health Fund) dive deep on the W26 Y Combinator batch and discuss key insights related to the Future of Health Fund coming out of one of the strongest biotech and health tech cohorts in recent history. The conversation covers how AI is reshaping drug discovery, replacing animal models with human biology representations, and acting as a co-pilot for scientists. From AI-powered primary care and revenue cycle automation to chronic disease management and elder care, they break down where they're seeing the most exciting founder activity — and what separates the companies worth backing from the AI wrappers that won't last. Plus: a look at one of Pioneer's standout portfolio exits — a psychedelics platform that sold its lead asset for over $1 billion after pioneering treatment-resistant depression therapy.

6 de abr de 202640 min